Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy

Trial Profile

Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Everolimus (Primary) ; Antineoplastics
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PACS11UNIRAD; UNIRAD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2016 Planned End Date changed from 1 Jan 2018 to 1 Jun 1931.
    • 02 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top